Pfizer Inc.

NYSE:PFE

Drug Manufacturers - General

Healthcare
$28.06 -2.72%

-$0.71 today

Market cap
$159.94B
Beta
0.29
P/E (TTM)
19.2
EPS (TTM)
$1.32
Dividend yield
6.82%
52W Low $23.11High $28.75

Volume 37.37M

Average 36.66M

PFE Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Pfizer Inc.NYSE: PFE

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $1.62B fell 0.2% year over year, ahead of the -3.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +9.2% a year.

Context

  • Depreciation & amortization amounted to 10.5% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -0.2% holds above the trailing-twelve-month pace of -3.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.62B+0.6% QoQ
Last fiscal yearDec 2025
$6.59B-6.0% YoY
LTMJun 2026
$6.58B-3.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.2%——
1 year-6.0%——
3-year CAGR+9.2%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
6.59B USD
Year-over-year change
-6.0%
4-year CAGR
+6.2%

Depreciation & Amortization vs competitors

How PFE compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.0% is the 6th highest of 11, against a peer median of -5.7%.
  • Depreciation & amortization amounts to 10.3% of revenue for PFE, versus a peer median of 8.9%.
PFE Competitors
Depreciation & Amortization for PFE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$6.72B USD+45.9%+14.3%10.1%
PFEPfizer Inc.LTM Jun 2026$6.58B USD-3.0%+9.2%10.3%
AZNAstraZeneca PLCLTM Sep 2026$6.41B USD+29.8%+3.0%10.3%
JNJJohnson & JohnsonLTM Sep 2026$5.97B USD-19.1%+2.5%6.0%
SNYSanofiLTM Jun 2026€5.88B EUR+22.9%+22.2%12.0%
ABBVAbbVie Inc.LTM Sep 2026$5.81B USD-29.7%-1.3%8.8%
NVSNovartis AGLTM Jun 2026$5.34B USD-11.0%-7.2%9.6%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$3.18B USD-51.1%-26.9%6.5%
GILDGilead Sciences, Inc.LTM Jun 2026$2.76B USD-0.4%+9.5%9.1%
GSKGSK plcLTM Jun 2026£2.21B GBP-34.0%+2.5%6.7%
LLYEli Lilly and CompanyLTM Jun 2026$2.1B USD+10.9%+9.5%2.6%
Peer median (excluding PFE) —-5.7%+2.7%8.9%

Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue81.29B101.18B59.55B63.63B62.58B
Cost of Revenue30.82B34.34B24.95B17.85B16.07B
Gross Profit50.47B66.83B34.6B45.78B46.51B
Gross Margin62.1%66.1%58.1%71.9%74.3%
Research & Development13.83B11.43B10.68B10.82B10.44B
Selling, General & Admin12.7B13.68B14.77B14.73B13.79B
Operating Expenses30.23B28.71B30.18B30.84B29.11B
Depreciation & Amortization5.19B5.06B6.29B7.01B6.59B
EBITDA30.79B41.03B9.56B18.13B16.78B
EBITDA Margin37.9%40.6%16.0%28.5%26.8%
Operating Income20.24B38.12B4.42B14.94B17.41B
Operating Margin24.9%37.7%7.4%23.5%27.8%
Interest Income36M251M1.62B545M603M
Interest Expense1.29B1.24B2.21B3.09B2.67B
Other Income / Expenses4.08B(3.39B)(3.36B)(6.92B)(9.89B)
Income Before Tax24.31B34.73B1.06B8.02B7.52B
Pre-Tax Margin29.9%34.3%1.8%12.6%12.0%
Income Tax Expense1.85B3.33B(1.12B)(28M)(266M)
Net Income21.98B31.37B2.12B8.03B7.77B
Net Margin27.0%31.0%3.6%12.6%12.4%
EPS (Basic)3.955.590.381.421.36
EPS (Diluted)3.885.470.371.411.36
Weighted Avg Shares5.6B5.61B5.64B5.66B5.68B
Weighted Avg Shares (Diluted)5.71B5.73B5.71B5.7B5.69B

Pfizer Inc.

NYSE:PFE

Intrinsic Alpha fair value

Locked

Current Price

$28.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.